Earnings8-K
Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
AVIR
Atea Pharmaceuticals, Inc.
A Boston drug developer that makes oral antiviral medicines for serious viral infections, with its lead program pairing bemnifosbuvir and ruzasvir against hepatitis C. It was founded in 2012 by Jean-Pierre Sommadossi, a co-founder of Pharmasset, the company behind the hepatitis C treatment sofosbuvir, sold as Sovaldi. Sommadossi helped build that earlier drug, and Atea carries forward the same nucleoside antiviral science.
CUSIP: 04683R106HealthcareUS1 holder